文献速递皮肤肿瘤

帕博利珠单抗治疗转移性黑色素瘤相关色素性皮损消退一例

A case report of disappearing pigmented skin lesions associated with pembrolizumab treatment for metastatic melanoma.
PubMed 文献 · Br J Dermatol · 2017-09-21

本文报告一名六十余岁转移性黑色素瘤男性患者,接受靶向PD-1受体的免疫检查点抑制剂帕博利珠单抗治疗后,出现色素性皮损变淡或消失、皮肤变浅及眉毛、睫毛、头皮和体毛发白。与基线三维全身摄影相比,日光性黑子、脂溢性角化及黑素细胞痣变淡或消失,提示PD-1抑制剂可能影响这些良性皮损的演变。

要点

  • PD-1抑制剂帕博利珠单抗可伴随色素性皮损变淡或消失及毛发变白。
  • 皮肤镜下改变表现为蓝灰色点状或颗粒状色素或颜色变淡,未见晕痣或周围炎症。
  • 一例皮肤镜示蓝灰色颗粒的皮损活检为伴噬黑素细胞的斑状脂溢性角化。

核心结论

  • 帕博利珠单抗治疗转移性黑色素瘤期间可出现色素性皮损变淡或消失、皮肤变浅及毛发变白,提示PD-1抑制剂可能影响良性皮肤病变的演变。

研究设计与样本

  • 单例病例报告:一名六十余岁转移性黑色素瘤男性,接受帕博利珠单抗治疗,采用基线高分辨率三维全身摄影及皮肤镜随访对比。

主要发现

  • 与基线三维全身摄影相比,日光性黑子、脂溢性角化及黑素细胞痣出现变淡或消失。
  • 皮肤镜随访中,改变后的皮损表现为蓝灰色点状或颗粒状色素或颜色变淡,未见其他可识别特征。
  • 未发现晕痣样皮损或伴周围炎症的皮损。
  • 一例皮肤镜示蓝灰色点状或颗粒状色素的改变皮损活检,判读为伴噬黑素细胞的斑状脂溢性角化。
  • 患者同时出现皮肤变浅及眉毛、睫毛、头皮和体毛发白。

临床怎么用

  • 对接受PD-1抑制剂的患者进行皮肤随访时,应关注色素性皮损变淡、消失及毛发变白等改变。
  • 对发生改变的色素性皮损可行皮肤镜随访,必要时活检以排除恶性病变。

局限性

  • 为单例病例报告,无法确定因果关系或发生率。
  • PD-1抑制对良性皮肤病变的影响仍需进一步研究阐明。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Pembrolizumab is an immune checkpoint inhibitor that targets the programmed cell death (PD)-1 receptor. Common cutaneous adverse side-effects of PD-1 inhibitors include maculopapular rash, pruritus, vitiligo and lichenoid skin and mucosal reactions. Here we describe a man in his sixties with metastatic melanoma treated with pembrolizumab who subsequently developed fading or disappearance of pigmented skin lesions, lightening of the skin, and poliosis of the eyebrows, eyelashes and scalp and body hair. Compared with baseline high-resolution three-dimensional total-body photography, we observed fading or disappearance of solar lentigines, seborrhoeic keratoses and melanocytic naevi, suggesting that PD-1 inhibitors may affect the evolution of these benign skin lesions. With dermatoscopic follow-up, altered lesions showed either blue-grey peppering/granularity or fading in colour without other identifiable features. No halo lesions or lesions with surrounding inflammation were identified. One changed pigmented lesion that showed blue-grey peppering/granularity on dermoscopy was biopsied and interpreted as a macular seborrhoeic keratosis with melanophages. Further studies are required to elucidate the effects of PD-1 inhibition on benign skin lesions.

来源:Br J Dermatol,查看原文。版权归原作者所有。

引用

  1. Wolner ZJ, Marghoob AA, Pulitzer MP, et al. A case report of disappearing pigmented skin lesions associated with pembrolizumab treatment for metastatic melanoma. Br J Dermatol. 2017. PMID: 28132411. doi:10.1111/bjd.15354

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。